Laser Vision Correction is eye surgery to correct nearsightedness, farsightedness and astigmatism. Corneal Specialist Rajesh Rajpal, M.D. is credited with being the first eye surgeon to perform Laser Vision Correction in the Washington DC area. During this time he served as a Principal Investigator for the FDA clinical trials that demonstrated the safety and efficacy of the treatment.
At See Clearly Vision, our doctors insist on performing the best possible laser technology for each patient, including All Laser Bladeless Custom Wavefront LASIK. We believe in a conservative approach to Laser Vision Correction, and will take the time necessary to review our examination results and answer your questions so that you can make an informed decision about Laser Eye Surgery.
LASIK is called “lamellar eye surgery” because it is performed between the layers of corneal tissue. This is accomplished by creating a very thin flap of corneal tissue, that is then lifted so that the laser energy can be applied to the inner layers of the cornea. This reshaping of the cornea allows for light rays to be focused in a crisp image on the retina, thus minimizing the need for an optical prescription. Because LASIK is performed under a flap of tissue that is then returned to its original position, patients typically report better postoperative comfort and faster healing times. As Corneal Specialists, the See Clearly surgeons have additional training, experience and expertise in Laser Eye Surgery, which offers our patients an added sense of confidence in the safety, efficacy and predictability of the procedure.
On April 25, 2008 the U.S. Food and Drug Administration's Ophthalmic Devices Panel convened to discuss post-LASIK quality-of-life issues. At that time, 140 patients--of the 7.6 million people who had undergone LASIK in the United States since the mid-1990s--had written letters of complaint to the FDA. The FDA followed up on these complaints by holding a hearing to see if new warnings about LASIK surgery were needed to alert consumers to the possibility of eye pain, dry eyes, blurred or double vision, or other problems. In 2007 a LASIK Study Task Force consisting of representatives from the Food and Drug Administration (FDA), the American Society of Cataract and Refractive Surgery, the American Academy of Ophthalmology, and the National Eye Institute was formed. The LASIK Study Task Force reviewed over 3000 clinical studies and reports on more than 16 million patients and reported a 95.4% patient satisfaction rate worldwide.